Menu
Search
|

Menu

Close
X

Biomarin Pharmaceutical Inc BMRN.OQ (NASDAQ Stock Exchange Global Select Market)

83.05 USD
-0.95 (-1.13%)
As of Feb 23
chart
Previous Close 84.00
Open 85.22
Volume 704,926
3m Avg Volume 468,763
Today’s High 86.00
Today’s Low 81.31
52 Week High 100.50
52 Week Low 78.50
Shares Outstanding (mil) 175.62
Market Capitalization (mil) 14,585.35
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.79 Mean rating from 24 analysts

KEY STATS

Revenue (mm, USD)
FY17
1,314
FY16
1,117
FY15
890
EPS (USD)
FY17
-0.910
FY16
-3.772
FY15
-1.079
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.62
Price to Sales (TTM)
vs sector
11.10
8.35
Price to Book (MRQ)
vs sector
5.20
5.22
Price to Cash Flow (TTM)
vs sector
--
25.88
Total Debt to Equity (MRQ)
vs sector
41.82
15.84
LT Debt to Equity (MRQ)
vs sector
28.96
12.39
Return on Investment (TTM)
vs sector
-4.31
13.63
Return on Equity (TTM)
vs sector
-5.72
15.39

EXECUTIVE LEADERSHIP

Jean-Jacques Bienaime
Chairman of the Board, Chief Executive Officer, Since 2015
Salary: $1,037,500.00
Bonus: --
Daniel Spiegelman
Chief Financial Officer, Executive Vice President, Since 2012
Salary: $530,192.00
Bonus: --
G. Eric Davis
Executive Vice President, General Counsel, Secretary, Since 2016
Salary: $409,593.00
Bonus: --
Jeff Ajer
Executive Vice President, Chief Commercial Officer, Since 2013
Salary: $490,385.00
Bonus: --
Robert Baffi
Executive Vice President - Technical Operations, Since 2009
Salary: $491,347.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

105 Digital Dr
NOVATO   CA   94949-8703

Phone: +1415.5066700

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.

SPONSORED STORIES